RESEARCH STUDY FOR CHILDREN WITH ADHD AND TDD Investigators at IU School of Medicine Department of Psychiatry are conducting a research study for children aged 8-17 with suspected ADHD and mood swings. The study examines the effect of an FDA approved medication on a child’s ability to regulate their emotions. This study involves 7 visits to our clinic and 2 MRI brain scans. Call 317-948-3472 for more details.

RESEARCH STUDY FOR CHILDREN WITH ADHD, OPPOSITIONAL DEFIANT DISORDER, OR CONDUCT DISORDER

Investigators at IU School of Medicine Department of Psychiatry are conducting a research study for children aged 10-14 with suspected ADHD, Oppositional Defiant Disorder, or Conduct Disorder and healthy control children with no psychiatric disorders or addiction history in their family. The study examines a child’s risk for drug addiction based on whether or not they have a father with a history of substance abuse. This study involves 1 visit to our clinic and an MRI brain scan. Call 317-948-3472 for more details.

THE NEUROBEHAVIORAL PHENOTYPE OF ANGELMAN SYNDROME

The Angelman Syndrome Clinic at the Riley Hospital Child and Adolescent Psychiatry Clinic is conducting a Research Study for individuals age 3 and older with Angelman Syndrome. Your 3 year or older child with Angelman Syndrome may qualify for this study involving psychological testing, structured surveys, and optional blood testing designed to describe behaviors and mental illnesses common to Angelman Syndrome.

Participation requirements and risks involved in this study will be disclosed prior to study enrollment. If you are interested in participating or would like more information, please contact us at (317) 944-9766.

AUTISM RESEARCH STUDY

The Section of Child & Adolescent Psychiatry at Indiana University School of Medicine is conducting a 12-week study designed to study the effects of acamprosate in individuals with autism and intellectual disability. Participants must be children between the ages of 5 and 17 with autism and intellectual disability.  Participants will receive study medication at no charge. 

For additional information about study requirements and study procedures, please call one of Dr. Craig Erickson’s research staff at (317) 948-9766 or at kidpsych@iupui.edu.

AUTISM RESEARCH STUDY

The Christian Sarkine Autism Treatement Center at IU School of Medicine Department of Psychiatry is conducting a 24-week parent training research study. Children must be between the ages of 3 and 7 with Autism, Asperger's Disorder, or PDD-NOS. Participation requirements, benefits, and risks will be disclosed prior to study enrollment.

For additional information about study requirements and study procedures, please contact us at (317)948-9766 or kidpsych@iupui.edu.

A RESEARCH STUDY OF AUTISM SPECTRUM DISORDERS

We’re doing a research study to learn more about an investigational drug. We want to know if the investigational drug is safe and if it helps to treat symptoms of Autism Spectrum Disorders. We’re looking for volunteers ages 5 to 21 who have been diagnosed with an Autism Spectrum Disorder and who exhibit certain behaviors such as listlessness and inactivity, isolation from other children and adults, or fixed facial expressions and lack of emotional response.

We’ll ask you and your child/dependent to come to The Christian Sarkine Autism Treatment Center at Riley Hospital for Children a total of 7 times over the course of about 5 months for study visits. Most visits will last between one and two hours. The first and last visit may last longer. A doctor will talk with you about how your child/dependent is doing during each of the visits. We’ll check his /her weight, height, pulse and blood pressure. We’ll also take blood samples from your child/dependent at certain visits and we’ll do an ECG (electrocardiogram) to check heart function at the beginning and end of the study. We’ll ask you to answer some written questions and record each dose of study medication taken by your child/dependent. For each visit to the office, a small payment may be offered to offset travel expenses.

If you take part in this study, there may or may not be direct medical benefit to your child/dependent. However, he/she will receive study-related medical care, monitoring, and frequent visits with the study doctor at no cost to you. We’ll give you information about Autism Spectrum Disorders and possible treatment options. This study may also help us learn to better care for others with Autism Spectrum Disorders in the future.

For more information about this study, please contact:

Kimberly A. Stigler, M.D.
Indiana University School of Medicine
(317)948-9766
kidpsych@iupui.edu

AUTISM RESEARCH STUDY

The section of Child & Adolescent Psychiatry at Indiana University School of Medicine is conducting a study designed to study the effects of acamprosate in individuals with autism. Participants must be children between the ages of 5 and 17 with autism.

Participants will receive study medication at no charge. For additional information about study requirements and study procedures, please call one of Dr. Craig Erickson's research staff at (317) 948-9766 or at kidpsych@iupui.edu.

A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF D-CYCLOSERINE FOR THE ENHANCEMENT OF SOCIAL SKILLS TRAINING IN PERVASIVE DEVELOPMENTAL DISORDERS

The Christian Sarkine Autism Treatment Center at Riley Hospital for Children is conducting a Research Study for 5-11 year old children who have Autism Spectrum Disorders. If your 5-11 year old child has Autism, Asperger's or PDD NOS, he or she may qualify for a research study involving an investigational study medication, social skills training, and clinic visits with a child psychiatrist and qualified research staff.

This 14-week study, conducted by Craig Erickson, M.D., of the Indiana University School of Medicine at the Christian Sarkine Autism Treatment Center, Riley Hospital for Children, is looking at this investigational study medication as a way of enhancing the effectiveness of social skills development.

Benefits of the study include: assessments, social skills training and study medication provided at no charge. Risks of the study include: being assigned to placebo or having side effects from the study medication, or the inconvenience of attending study visits. Participation requirements plus additional benefits and risks involved in this study will be disclosed prior to study enrollment.

If you are interested in participating or would like more information, please call the Christian Sarkine Autism Treatment Center at (317) 948-9766 or email: kidpsych@iupui.edu

PERVASIVE DEVELOPMENT DISORDERS RESEARCH STUDY

The Section of Child & Adolescent Psychiatry at Indiana University School of Medicine is conducting a study designed to study the effects of aripiprozale in children with Pervasive Developmental Disorders (PDD's). Participants must be children between the ages of 5 and 17 with Pervasive Developmental Disorder (PDD) as well as behavioral difficulties such as irritability, tantrums, aggression and self-injurious behavior. Participants must have no medical illness and not have had a previous adequate trial of aripiprozale. Participants will receive study medication at no charge. For additional information about study requirements and study procedures, please contact us at (317) 948-9766 or kidpsych@iupui.edu

For more information about this study, click here.

AN OPEN-LABEL (PART ONE) AND A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED (PART TWO) STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF MEMANTINE IN PEDIATRIC PATIENTS WITH AUTISM, ASPERGER'S DISORDER OR PDD.

The Christian Sarkine Autism Treatment Center at Riley Hospital for Children is conducting a research study for 6-12 year old children with Autism, Asperger's Disorder and PDD. If your 6-12 year old c hild has Autism, Asperger's Disorder, or PDD he or she may qualify for a research study involving an investigational study medication and clinic visits with a c hild psychiatrist and qualified research staff at no charge. This 15-week study, conducted by Dr. Kimberly Stigler, of the Indiana University School of Medicine is looking at the use of the medication memantine, as a treatment for improving the core symptoms of autism. Benefits of the study include: improvements of symptoms of autism, medical asessments and study drug provided at no charge. Risks include: discomfort associated with blood draws, being assigned to placebo or side effects from study medication. Participation requirements plust additional benefits and risks involved in this study will be disclosed prior to study enrollment. If you are interested in participating or would like more information, please contact the Christian Sarkine Autism Treatment Center at (317) 948-9766 or kidpsych@iupui.edu

STUDIES TO DETERMINE THE GENETIC AND ENVIRONMENTAL FACTORS ASSOCIATED WITH BIPOLAR DISORDER

John Nurnberger, Jr., M.D., Ph.D., at Indiana University School of Medicine and a collaborative team of psychiatric geneticists are conducting studies, sponsored by the National Institute of Mental Health. The studies are an attempt to identify genes and environmental factors that may be responsible for Bipolar Disorder. This information will hopefully lead to the development of new treatments for this disorder.

For more information, please call us toll free at 1-888-750-2201, visit our website,
http://www.iupui.edu/~bipolar or email at bipolar@iupui.edu.

STUDY OF BIPOLAR DISORDER (FLYER)

RESEARCH STUDY FOR CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER

Investigators at IU School of Medicine Department of Psychiatry are conducting a research study to test an investigational medication for children and adolescents, age 10-17, with Bipolar I Disorder. Eligible participants must be currently taking a bipolar medication (s). Participation includes approximately 42 visits, potentially lasting up to 15 months. Participants will receive study procedures, mental health evaluations, and medication or placebo at no charge. Compensation is $90 for the initial screening visit (visit 1) and $30 for each additional visit to offset travel expenses.

To learn more information about this study and its requirements, call Riley Child and Adolescent Psychiatry Clinic at 317-944-1128 or email kidpsych@iupui.edu.

For more information about this study, click here.

PERSONS WITH BIPOLAR DISORDER OR MOOD SWINGS

Do you have Bipolar Disorder or mood swings? Perhaps you can help us! The Indiana University Medical Center Mood Disorders Clinic is searching for people between the ages of 18-60 with bipolar disorder or mood swings to participate in a clinical trial. Qualified participants will receive medical and psychiatric exams at no cost. The study consists of questionnaires and a brain scan (MRI). At that time participants have the option to continue on for further treatments with medication. Risks associated with the study will be disclosed prior to study initiation. For more information, call (317)944-0318. Please leave your name and a phone number at which you can easily be reached. For more information about this study, click here.

DEPRESSION STUDY

Are you feeling low? Have you lost interest in the people and things that used to bring you joy? Do you lack the drive and energy to do the things you would like to do? Are you tired of feeling depressed and anxious?

If you answered YES to any of the questions above, you may be eligible to take part in a study for depression being conducted by the Indiana University School of Medicine Adult Psychiatry Clinic. We are looking for individuals between the ages of 18 and 60 who are either suffering from depression with anxiety and are not currently on any medications for depression and anxiety.

This study has 9 visits over about 12 weeks and involves treatment with the medication (quetiapine, also known as Seroquel XR®) and brain scans (MRI). All study procedures and study medication are provided to subjects free of charge. Compensation is up to $200.

Taking part in a study is a serious decision. All risks and benefits will be discussed with you so that you can make the decision that's right for you.

If you are interested, please call (317) 944-0318

For more information about this study, click here.

FRAGILE X SYNDROME RESEARCH STUDY

Craig Erickson, M.D. of The Section of Child & Adolescent Psychiatry at Indiana University School of Medicine is conducting a study designed to study the effects of acamprosate in individuals with Fragile X syndrome.

Participants must be adults between the ages of 18 and 50 with Fragile X syndrome. Participants will receive study medication at no charge. This study will also incorporate a Biomarker Assay and is looking for adults between the ages of 18 and 50 with an Autism Spectrum Disorder who are not taking acamprosate.

For additional information about study requirements and study procedures, please contact one of Dr. Craig Erickson’s research staff at (317) 278- 9766 or kidpsych@iupui.edu

FRAGILE X SYNDROME STUDY

We're doing a research study to learn more about an investigational drug. We want to know if the investigational drug is safe and if it helps to treat symptoms of Fragile X Syndrome. We're looking for volunteers ages 12 to 25 who have been diagnosed with Fragile X Syndrome and who are socially impaired. For example, volunteers who often prefer to be alone, don't like being touched, don't react to other people, or have fixed facial expressions.

We’ll ask you and your child/dependent to come to The Christian Sarkine Autism Treatment Center at Riley Hospital for Children a total of 6 times over the course of about 4 months for study visits. Most visits will last between one and two hours. The last visit may last up to 3 hours. A doctor will talk with you about how your child/dependent is doing during the visits. We’ll check his /her weight, height, pulse and blood pressure. We’ll ask you to answer some written questions. We’ll also take a blood sample from your child/dependent at 3-4 visits and we’ll do an ECG to check heart function during 2 visits. For each visit to the office, a small stipend will be offered to offset travel expenses.

If you take part in this study, there may or may not be direct medical benefit to your child/dependent. However, he/she will receive study-related medical care, monitoring, and frequent visits with a study doctor. We’ll give you information about Fragile X Syndrome and possible treatment options. This study may also help us learn to better care for others with Fragile X Syndrome in the future.

For more information about this study, please contact:

Craig Erickson, M.D.
Indiana University School of Medicine
(317)948-9766
kidpsych@iupui.edu

CAFQ056A2212 AND FRAGILE X SYNDROME

The Indiana University School of Medicine is conducting a 20-Week research study designed to study the safety and tolerability of an investigational drug (not approved by the FDA) CAFQ056A2212 in individuals with fragile X syndrome. Participants must be adults between the ages of 18 and 45 with fragile X syndrome. Participants and caregivers will be required to complete questionnaires, record all the study medication taken and attend visits every two to four weeks for 20 Weeks. Participants will be expected to attend nine clinic visits at the Christian Sarkine Autism Treatment Center at Riley Hospital Outpatient Clinic (ROC). Participants will receive study medication at no charge.

If you would like to find out more about this research study conducted by Craig Erickson, M.D. of the Fragile X Research and Treatment Center at Riley Hospital, please contact a member of the research team at (317) 948-9766 or at kidpsych@iupui.edu.

THE NEUROBEHAVIORAL PHENOTYPE OF FRAGILE X SYNDROME

The Child & Adolescent Psychiatry Fragile X Syndrome Clinic at Riley Hospital for Children is conducting a Research Study for individuals age 3 and older with Fragile X Syndrome. Your 3 year or older child with Fragile X Syndrome may qualify for this study involving psychological testing & structured surveys designed to describe behaviors & mental illnesses common to Fragile X Syndrome. Participation requirements and risks involved in this study will be disclosed prior to study enrollment. If you are interested in participating or would like more information, please contact us at (317) 948-9766.

For more information about this study, click here.

RESEARCH STUDY FOR ADOLESCENTS WITH JUVENILE PRIMARY FIBROMYALGIA SYNDROME

Investigators at IU School of Medicine Department of Psychiatry are conducting a research study of an investigational medication for adolescents, age 13-17, with Juvenile Primary Fibromyalgia Syndrome (JPFS). Study involves approximately 16 visits and lasts up to 41 weeks. Participants receive study procedures, mental health evaluations, and medication or placebo at no charge. Call 317-944-1128 or email kidpsych@iupui.edu

SCHIZOPHRENIA FAMILY STUDY

Drs. Brian O'Donnell Ph.D. and Anantha Shekhar M.D., Ph.D. from the Neuroscience Clinical Research Center at Indiana University School of Medicine are conducting a Schizophrenia Family Study.

There is evidence that schizophrenia may be influenced by genetic or medical factors in a family, and this project is seeking to identify such shared factors. We are gathering information from both patients and their relatives (parents, children or siblings) on tests of vision, learning, memory, attention and by collecting brainwave activity, to investigate the relationship between genetic relatedness and the symptoms of schizophrenia.

Our study is run from LaRue Carter Hospital in Indianapolis, and you will receive payment for participation. Transportation can be provided if needed.

If you or someone you know either has a diagnosis of schizophrenia or is related to someone who is, and would like to participate in our research project, please call (317) 941-4502.

SCHIZOPHRENIA STUDY

The Indiana University Clinical and Cognitive Neuroscience Center(CCNC) in Indianapolis conducts research on the causes, consequences and treatment of schizophrenia. The Center is currently seeking family members of individuals with schizophrenia for a new research study. The study seeks to identify what genes are associated at risk for schizophrenia, and which genes may be protective. Participants will receive interviews, EEG testing, and computerized cognitive testing. The study takes between 4 and 8 hours and can be scheduled on different days. No injections, change in treatment or blood collection are required. Participants are paid for their time.

Further information can be obtained from the:
Clinical and Cognitive Neuroscience Center
Larue Carter Memorial Hospital
2601 Cold Springs Rd.
Indianapolis, IN. 46222
Phone: (317)941-4502
Email: eeglab@indiana.edu